Otsuka Holdings Co., Ltd. (OTSKY)
USD 27.55
(-0.4%)
USD 27.55
(-0.4%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 69.2 Billion JPY | -53.87% |
| 2022 | 150 Billion JPY | -7.68% |
| 2021 | 162.48 Billion JPY | -10.67% |
| 2020 | 181.87 Billion JPY | -3.51% |
| 2019 | 188.48 Billion JPY | 34.66% |
| 2018 | 139.97 Billion JPY | -20.9% |
| 2017 | 176.96 Billion JPY | -8.77% |
| 2016 | 193.97 Billion JPY | -19.02% |
| 2015 | 239.52 Billion JPY | 957.05% |
| 2014 | 22.66 Billion JPY | 87.1% |
| 2013 | 12.11 Billion JPY | -61.83% |
| 2012 | 31.73 Billion JPY | -11.42% |
| 2011 | 35.82 Billion JPY | -48.81% |
| 2010 | 69.98 Billion JPY | -28.9% |
| 2009 | 98.43 Billion JPY | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q1 | 68.67 Billion JPY | -0.76% |
| 2024 Q2 | 67.9 Billion JPY | -1.13% |
| 2023 Q3 | 125.75 Billion JPY | -1.07% |
| 2023 FY | 69.2 Billion JPY | -53.87% |
| 2023 Q4 | 69.2 Billion JPY | -44.97% |
| 2023 Q1 | 127.31 Billion JPY | -15.12% |
| 2023 Q2 | 127.11 Billion JPY | -0.16% |
| 2022 Q3 | 154.99 Billion JPY | -1.41% |
| 2022 Q4 | 150 Billion JPY | -3.22% |
| 2022 Q2 | 157.2 Billion JPY | -1.51% |
| 2022 FY | 150 Billion JPY | -7.68% |
| 2022 Q1 | 159.61 Billion JPY | -1.76% |
| 2021 Q2 | 169.46 Billion JPY | -5.66% |
| 2021 Q3 | 170.56 Billion JPY | 0.65% |
| 2021 Q4 | 162.48 Billion JPY | -4.74% |
| 2021 FY | 162.48 Billion JPY | -10.67% |
| 2021 Q1 | 179.62 Billion JPY | -1.24% |
| 2020 Q2 | 177.58 Billion JPY | -3.86% |
| 2020 FY | 181.87 Billion JPY | -3.51% |
| 2020 Q3 | 181.79 Billion JPY | 2.37% |
| 2020 Q4 | 181.87 Billion JPY | 0.04% |
| 2020 Q1 | 184.71 Billion JPY | -2.0% |
| 2019 FY | 188.48 Billion JPY | 34.66% |
| 2019 Q1 | 270.61 Billion JPY | 93.34% |
| 2019 Q4 | 188.48 Billion JPY | -24.68% |
| 2019 Q3 | 250.26 Billion JPY | -0.77% |
| 2019 Q2 | 252.19 Billion JPY | -6.81% |
| 2018 FY | 139.97 Billion JPY | -20.9% |
| 2018 Q4 | 139.97 Billion JPY | -11.91% |
| 2018 Q3 | 158.89 Billion JPY | 1.04% |
| 2018 Q2 | 157.25 Billion JPY | -9.27% |
| 2018 Q1 | 173.32 Billion JPY | -2.06% |
| 2017 Q1 | 190.39 Billion JPY | -1.85% |
| 2017 FY | 176.96 Billion JPY | -8.77% |
| 2017 Q4 | 176.96 Billion JPY | 3.14% |
| 2017 Q3 | 171.56 Billion JPY | -2.28% |
| 2017 Q2 | 175.56 Billion JPY | -7.79% |
| 2016 FY | 193.97 Billion JPY | -19.02% |
| 2016 Q4 | 193.97 Billion JPY | -4.25% |
| 2016 Q3 | 202.57 Billion JPY | -0.92% |
| 2016 Q2 | 204.44 Billion JPY | -8.96% |
| 2016 Q1 | 224.57 Billion JPY | -6.24% |
| 2015 Q2 | 272 Billion JPY | 57.77% |
| 2015 Q3 | 268.94 Billion JPY | -1.12% |
| 2015 Q4 | 239.52 Billion JPY | -10.94% |
| 2015 Q1 | 172.41 Billion JPY | 0.0% |
| 2015 FY | 239.52 Billion JPY | 957.05% |
| 2014 Q3 | 19.87 Billion JPY | 2.24% |
| 2014 FY | 22.66 Billion JPY | 87.1% |
| 2014 Q2 | 19.43 Billion JPY | -2.68% |
| 2014 Q1 | 19.97 Billion JPY | 108.84% |
| 2013 Q3 | 8.64 Billion JPY | 2.29% |
| 2013 Q4 | 9.56 Billion JPY | 10.59% |
| 2013 Q1 | 12.11 Billion JPY | 84.37% |
| 2013 FY | 12.11 Billion JPY | -61.83% |
| 2013 Q2 | 8.45 Billion JPY | -30.2% |
| 2012 FY | 31.73 Billion JPY | -11.42% |
| 2012 Q4 | 6.56 Billion JPY | -60.05% |
| 2012 Q3 | 16.44 Billion JPY | -35.17% |
| 2012 Q2 | 25.36 Billion JPY | -20.08% |
| 2012 Q1 | 31.73 Billion JPY | 16.07% |
| 2011 Q2 | 29.52 Billion JPY | -17.59% |
| 2011 Q1 | 35.82 Billion JPY | -24.6% |
| 2011 Q3 | 27.96 Billion JPY | -5.29% |
| 2011 Q4 | 27.34 Billion JPY | -2.22% |
| 2011 FY | 35.82 Billion JPY | -48.81% |
| 2010 Q4 | 47.51 Billion JPY | -0.85% |
| 2010 Q3 | 47.92 Billion JPY | -22.25% |
| 2010 Q1 | 69.98 Billion JPY | 5.52% |
| 2010 FY | 69.98 Billion JPY | -28.9% |
| 2010 Q2 | 61.63 Billion JPY | -11.93% |
| 2009 Q3 | 66.54 Billion JPY | -5.26% |
| 2009 FY | 98.43 Billion JPY | 0.0% |
| 2009 Q4 | 66.32 Billion JPY | -0.33% |
| 2009 Q2 | 70.24 Billion JPY | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| AstraZeneca PLC | 22.33 Billion USD | -209.85% |
| Bristol-Myers Squibb Company PFD CONV 2 | 38.18 Billion USD | -81.232% |
| CSPC Pharmaceutical Group Limited | 107.05 Million USD | -64537.86% |
| Clarus Therapeutics Holdings, Inc. | - USD | -Infinity% |
| Novartis AG | 20.03 Billion USD | -245.413% |
| PT Kalbe Farma Tbk. | 19.39 Million USD | -356750.099% |